Your Unfair Advantage - Twist NGS Target Enrichment Solutions

Date & Time

October 20, 2021 | 10:00am - 12:00pm SGT

Seminar Description

At Twist Bioscience, we combine precise oligonucleotide synthesis with a scalable silicon-based manufacturing platform to generate high-performing probe panels for NGS target enrichment. 


Twist’s Custom Panels can be designed and built to cover a wide range of panel sizes, target regions, and multiplexing requirements — all with the exceptional and consistent performance you’ve come to expect from Twist’s NGS solutions. Come join us in this online seminar to hear from our customers on how Twist’s NGS solutions enable them to discover more in human genomics.


In this seminar, you will…

  • Discover the various challenges in handling clinical research samples and how targeted NGS can be optimized and implemented in routine practice
  • Learn how custom NGS panels enabled more cost-effective sequencing of samples in a service laboratory setting
  • Find out how new technologies — from improved exome panel designs and bioinformatics to the integration of transcriptomics — drive change in diagnostic research
  • Hear how targeted methylation sequencing of 13 hereditary breast cancer (HBC) gene promoter regions enabled the study of inherited promoter hypermethylation and its contribution to the disease
Seminar Registration

Professor Ian Campbell

Co-Head of the Women’s Cancer Program
Peter MacCallum Cancer Centre
Professor Campbell is co-Head of the Women’s Cancer Program at the Peter MacCallum Cancer Centre and Professor in the Sir Peter MacCallum Department of Oncology at the University of Melbourne, Australia and Principal investigator of the Lifepool study (www.lifepool.org).  Professor Campbell has over 30 years research experience into the somatic and germline genetics of breast and ovarian cancer exemplified by seminal discoveries in the origins of ovarian cancer and the first identification of mutations in a PI3K pathway gene which are now among the most important therapeutic targets in cancer. He was a pioneer in applying next generation sequencing technology to the identification of new cancer predisposition genes and in population-based genetic testing for high-risk cancer predisposition genes.

Dr. Nayoung K. D. Kim

Director, Genomics Biz Division
GENINUS Inc.
Dr Kim graduated with a PhD in bioinformatics. After graduation, Dr Kim worked as a senior researcher at Samsung Genome Institute (Samsung Medical Center) and worked as a leader in the development of NGS-based panel technology. In 2019, Dr Kim joined GENINUS, a spin-off company of SMC, and is currently in charge of technology commercialization.

Associate Professor Sebastian Lunke

Head of Division of Genetics and Genomics
Victorian Clinical Genetics Services
A/Prof Sebastian Lunke is the Head of Division of Genetics and Genomics at VCGS and MCRI. Following his PhD in epigenetics and working as a post-doctoral research fellow at the University of Melbourne on assay development for cancer genomics, he started re-training as a medical scientist by joining the Faculty of Science at the Royal College of Pathologist Australasia as the first trainee fellow in 2014. Today, his team at the Victorian Clinical Genetics Service constitutes one of the largest NATA accredited clinical genetics and genomics laboratories in Australia, with a strong focus on translating novel technologies into clinical practise.

Dr. Sakthivel Murugan SM

Vice President - Lab Operations
MedGenome Labs Ltd
Dr. Sakthivel Murugan S.M completed his Ph.D. in Human Genetics from BITS, Pilani University, and he has been working in the field of genetic diagnosis over the last 15 years. He has more than 12 years of experience in NGS and NGS applications and has been involved in setting up, optimizing and running the largest genomic centre in India, the MedGenome Labs Ltd. Currently. Dr. Sakthivel is the Vice President of Lab Operations and Genomic Medicine in MedGenome and is a part of the leadership team in MedGenome Labs. He is completely responsible for lab operations which conducts more than 400+ CAP accredited tests. Heading the test validation department, he is part of the team planning, validating and implementing new tests, including NGS oncology and non-oncology panels. Also, Dr. Sakthivel is involved in designing new NGS panels, ensuring most of the tests are run in custom developed panels, thereby ensuring low cost per test.
©. All Rights Reserved Twist Bioscience.